NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

X4 Pharmaceuticals, Inc. (XFOR) Stock Analysis

X4 Pharmaceuticals, Inc. (XFOR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

XFOR

$3.01

−$0.01 (−0.33%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XFOR with… →

XFOR Key Statistics

As of Oct 21, 2026
Trading
Open
$3.02
Previous Close
$3.02
Day's Range
2.88–3.12
52-Week Range
2.43–4.83
Volume
406.82K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.46
Valuation
Market Cap
$298.43M
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.83
Financials (FY)
Revenue (FY)
$35.11M+1,273.21%
Net Income (FY)
−$79.20M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
99.15M
1-Year Return
−4.14%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
840.79K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, XFOR closed at $3.01, −4.14% over 1 year.

X4 Pharmaceuticals, Inc. (XFOR) has a market capitalization of $298.43M.

In fiscal 2025, XFOR reported revenue of $35.11M.

XFOR Stock Return by Calendar Year

X4 Pharmaceuticals, Inc. (XFOR) return since Nov 2017: what $10,000 became

1 year
$10,000 $9,586
−4.14%
5 years
$10,000 $203
−97.97%
Since Nov 2017
$10,000 $12
−99.88%

If you had invested $10,000 in X4 Pharmaceuticals, Inc. (XFOR) at the close on November 16, 2017, the earliest close on record here, it would have been worth $12 at the close on October 21, 2026: −99.88% in total, −52.95% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.75%
2025−81.83%
2024−12.51%
2023−15.51%
2022−56.64%
2021−64.39%
2020−39.91%
2019−23.13%
2018−81.82%
2017 (partial year)−9.05%

As of October 21, 2026.

XFOR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$35.11M−$79.20M−225.6%
2024$2.56M−$37.45M−1,464.6%
2023$0.00−$101.17M—
2022$0.00−$93.87M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$35.11M$29.36M−$86.88M−$79.20M−225.6%
2024$2.56M$1.76M−$141.40M−$37.45M−1,464.6%
2023$0.00$0.00−$107.52M−$101.17M—
2022$0.00$0.00−$88.08M−$93.87M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XFOR Valuation vs Biotechnology Median

Median of 608 stocks
MetricXFORBiotechnology medianvs median
P/S ratio18.8313.3042% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values X4 Pharmaceuticals, Inc. (XFOR) at $298.43M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 45 employees.

XFOR last closed at $3.01 on October 21, 2026. That is −$0.01 (−0.33%) against the previous close. Over the past 52 weeks the price has ranged from $2.43 to $4.83. The latest close sits 23.87% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $35.11M. Against the prior fiscal year total of $2.56M, that is a change of +1,273.21%. The same year closed with a net loss of $79.20M.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $35.11M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

Measured against sales, the shares trade at 18.83 times revenue. On price-to-sales that is 41.61% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.46. Annualized volatility over the trailing 8 years is 138.46%. The trailing one-year total return is −4.14%. Measured over 5 years, that is −54.15% a year compounded.

Growth & Income

The record shows no dividend for XFOR.

So far in 2026 the total return is −24.75%. The strongest complete calendar year on file is 2024 at −12.51%; the weakest is 2025 at −81.83%. Of the 8 complete calendar years on file, 0 finished higher.

Peer Comparison

X4 Pharmaceuticals, Inc. (XFOR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
X4 Pharmaceuticals, Inc. XFOR $298.43M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Visit website →